Document Detail


Causes of, and therapeutic approaches for, proton pump inhibitor-resistant gastroesophageal reflux disease in Asia.
MedLine Citation:
PMID:  21180528     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Proton pump inhibitors (PPIs) are the most widely used drugs for treatment of gastroesophageal reflux disease. However, approximately 20% of patients with reflux esophagitis and 40% of those with nonerosive reflux diseases complain of troublesome symptoms, even during treatment with PPIs. In patients with reflux esophagitis, dose escalation and co-administration with a histamine H(2)-receptor antagonist are potential approaches, since the major cause of PPI resistance is incomplete suppression of gastric acid secretion. On the other hand, for patients with nonerosive reflux disease, switching from PPIs to pain modulators is often necessary for improvement of symptoms, since 25% of patients with nonerosive reflux disease have symptoms not caused by gastroesophageal acid reflux. Therapeutic approaches for PPI-resistant patients with reflux esophagitis and nonerosive reflux diseases are considered according to pathogenesis.
Authors:
Yoshikazu Kinoshita; Shunji Ishihara
Related Documents :
21301888 - Microalbuminuria: causes and implications.
21174138 - Parkinson's disease in china.
21165698 - Chronic chagas' heart disease: a disease on its way to becoming a worldwide health prob...
21090968 - The pathogenesis of systemic sclerosis.
10479088 - Effects of malathion on disease susceptibility in woodhouse's toads.
10961598 - Immunosuppressors for inflammatory bowel disease: how long is long enough?
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Therapeutic advances in gastroenterology     Volume:  1     ISSN:  1756-283X     ISO Abbreviation:  Therap Adv Gastroenterol     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2010-12-24     Completed Date:  2011-07-14     Revised Date:  2011-07-19    
Medline Journal Info:
Nlm Unique ID:  101478893     Medline TA:  Therap Adv Gastroenterol     Country:  England    
Other Details:
Languages:  eng     Pagination:  191-9     Citation Subset:  -    
Affiliation:
Department of Gastro-enterology and Hepatology, Shimane University School of Medicine, Izumo, Shimane, Japan kinosita@med.shimane-u.ac.jp.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment options for nonalcoholic Fatty liver disease.
Next Document:  Current status of therapy in autoimmune liver disease.